Dr. Lui Franciosi, PhD
Chief Executive Officer
Dr. Franciosi has more than 20 years of experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he acted as the Chief Operating Officer at Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior to Verona Pharma, Dr. Franciosi completed his post-doctoral research in COPD progression modeling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. He obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada – and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.
David Alexander, CPA /CA
Chief Financial Officer
Mr. Alexander holds a Bachelor of Commerce in Finance from The University of British Columbia. His past achievements include; CFO of Arakis Energy Corporation, an international oil and gas development company, and managed the company’s growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company (Nasdaq: CRME).
Dr. Lui Franciosi
We have the skillset and the abilities to potentially substantiate claims surrounding marijuana for medicinal use. Not only from a scientific, but an intellectual property point of view, protecting our research and discovery in this exciting space.